文献速递病毒性肝炎艾滋病与性传播感染

丙型肝炎治疗资格标准对HIV感染者全因死亡率的影响

The Effects of Hepatitis C Treatment Eligibility Criteria on All-cause Mortality Among People With Human Immunodeficiency Virus.
PubMed 文献 · Clin Infect Dis · 2019-01-01

该研究基于3056名HIV成人(1994-2015年)使用参数g公式估计不同DAA准入政策下10年全因死亡率。限制性DAA准入政策可能降低生存率。

要点

  • 限制性DAA准入政策可能较随机治疗同等比例患者降低生存率

核心结论

  • 限制性DAA准入政策可能较随机治疗同等比例HIV/HCV合并感染者降低生存率。

研究设计与样本

  • 研究人群为1994年10月1日至2015年9月30日Women's Interagency HIV Study和Multicenter AIDS Cohort Study中3056名HIV成人。
  • 使用参数g公式估计四种DAA准入政策下10年全因死亡率。

临床怎么用

  • 临床应关注限制性DAA准入政策对HIV/HCV合并感染者生存的潜在不利影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The cost of direct-acting antivirals (DAAs) for hepatitis C virus (HCV) prompted many payers to restrict treatment to patients who met non-evidence-based criteria. These restrictions have implications for survival of people with HCV, especially for people with human immunodeficiency virus (HIV)/HCV coinfection who are at high risk for liver disease progression. The goal of this work was to estimate the effects of DAA access policies on 10-year all-cause mortality among people with HIV. METHODS: The study population included 3056 adults with HIV in the Women's Interagency HIV Study and Multicenter AIDS Cohort Study from 1 October 1994 through 30 September 2015. We used the parametric g-formula to estimate 10-year all-cause mortality under DAA access policies that included treating (i) all people with HCV; (ii) only people with suppressed HIV; (iii) only people with severe fibrosis; and (iv) only people with HIV suppression and severe fibrosis. RESULTS: The 10-year risk difference of treating all coinfected persons with DAAs compared with no treatment was -3.7% (95% confidence interval [CI], -9.1% to .6%). Treating only those with suppressed HIV and severe fibrosis yielded a risk difference of -1.1% (95% CI, -2.8% to .6%), with 51% (95% CI, 38%-59%) of coinfected persons receiving DAAs. Treating a random selection of 51% of coinfected persons at baseline decreased the risk by 1.9% (95% CI, -4.7% to .3%). CONCLUSIONS: Restrictive DAA access policies may decrease survival compared to treating similar proportions of people with HIV/HCV coinfection with DAAs at random. These findings suggest that lives could be saved by thoughtfully revising access policies.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Breskin A, Westreich D, Hurt CB, et al. The Effects of Hepatitis C Treatment Eligibility Criteria on All-cause Mortality Among People With Human Immunodeficiency Virus. Clin Infect Dis. 2019. PMID: 30615096. doi:10.1093/cid/ciz008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。